We describe recovery of vision and postreceptor retinal function but not photoreceptor function following severe, acute visual impairment associated with high-dose desferoxamine (DFO) used to chelate iron in a 36-year-old woman with β-thalassemia major.1,2 Survival of patients with β-thalassemia necessitates long-term transfusion with consequent iron overload of vital organs, for which chelation therapy is mandatory.
Lu M, Hansen RM, Cunningham MJ, Eklund SE, Fulton AB. Effects of Desferoxamine on Retinal and Visual Function. Arch Ophthalmol. 2007;125(11):1581-1582. doi:10.1001/archopht.125.11.1581